Penserra Capital Management’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-6,528
| Closed | -$206K | – | 1317 |
|
|
2023
Q3 | $206K | Sell |
6,528
-105
| -2% | -$3.31K | ﹤0.01% | 734 |
|
|
2023
Q2 | $270K | Buy |
6,633
+273
| +4% | +$11.1K | 0.01% | 696 |
|
|
2023
Q1 | $237K | Buy |
6,360
+740
| +13% | +$27.6K | ﹤0.01% | 659 |
|
|
2022
Q4 | $196K | Sell |
5,620
-3,152
| -36% | -$110K | ﹤0.01% | 697 |
|
|
2022
Q3 | $490K | Buy |
8,772
+6,656
| +315% | +$372K | 0.01% | 435 |
|
|
2022
Q2 | $109K | Buy |
2,116
+768
| +57% | +$39.6K | ﹤0.01% | 753 |
|
|
2022
Q1 | $97K | Buy |
+1,348
| New | +$97K | ﹤0.01% | 853 |
|
|
2021
Q4 | – | Sell |
-1,680
| Closed | -$225K | – | 1485 |
|
|
2021
Q3 | $225K | Buy |
1,680
+130
| +8% | +$17.4K | ﹤0.01% | 598 |
|
|
2021
Q2 | $250K | Buy |
1,550
+20
| +1% | +$3.23K | ﹤0.01% | 593 |
|
|
2021
Q1 | $122K | Buy |
1,530
+165
| +12% | +$13.2K | ﹤0.01% | 662 |
|
|
2020
Q4 | $74K | Buy |
1,365
+861
| +171% | +$46.7K | ﹤0.01% | 627 |
|
|
2020
Q3 | $10K | Buy |
+504
| New | +$10K | ﹤0.01% | 813 |
|